Preventive agent for carcinogenesis of liver cancer containing quinone-based compound as active ingredient
The present invention provides a safe and effective drug to prevent carcinogenesis of liver cancer derived, above all, from hepatitis C virus cirrhosis. The present invention provides a preventive agent for carcinogenesis of liver cancer containing menatetrenone as an active ingredient, and is effective in preventing the carcinogenesis of liver cancer by administration of such a preventive agent.
1 . A preventive agent for carcinogenesis of liver cancer, comprising menatetrenone as an active ingredient.
2 . A preventive agent for carcinogenesis of cancer derived from chronic liver disease, comprising menatetrenone as an active ingredient.
3 . A preventive agent for carcinogenesis of liver cancer derived from cirrhosis, comprising menatetrenone as an active ingredient.
4 . A preventive agent for carcinogenesis of liver cancer derived from hepatitis virus cirrhosis, comprising menatetrenone as an active ingredient.
5 . A preventive agent for carcinogenesis of liver cancer derived from hepatitis C virus cirrhosis, comprising menatetrenone as an active ingredient.
6 . A method for preventing carcinogenesis of liver cancer, comprising administering menatetrenone.
7 . A method for preventing carcinogenesis of cancer derived from chronic liver disease, comprising administering menatetrenone.
8 . A method for preventing carcinogenesis of live cancer derived from chronic liver disease, comprising administering menatetrenone.
9 . A method for preventing carcinogenesis of live cancer derived from hepatitis virus cirrhosis, comprising administering menatetrenone.
10 . A method for preventing carcinogenesis of live cancer derived from hepatitis C virus cirrhosis, comprising administering menatetrenone.
11 . A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer.
12 . A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of cancer derived from chronic liver disease.
13 . A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer derived from cirrhosis.
14 . A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer derived from hepatitis virus cirrhosis.
15 . A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer derived from hepatitis C virus cirrhosis.